Adding Idasanutlin to Cytarabine Does Not Improve OS in Relapsed/Refractory AML
Researchers sought to determine whether adding idasanutlin to cytarabine would improve OS in patients with relapsed or refractory acute myeloid leukemia.
Researchers sought to determine whether adding idasanutlin to cytarabine would improve OS in patients with relapsed or refractory acute myeloid leukemia.
Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.
The time from cytohistological diagnosis to treatment initiation was longer in 2019 than in 2020.
Perioperative COVID-19 was associated with a 30-day mortality rate of 26%.
Education, communication, and coordination are key.
Researchers sought to determine what factors may help predict what patients with MDS or AML would respond to treatment with azacitidine.
Researchers sought to determine whether patients with RRMM with ocular events induced by belantamab mafodotin would recover without discontinuing treatment.
Researchers evaluated the rates and significance of HFE variants in a population of patients with MDS.
Researchers sought to determine whether whole-genome sequencing may be a better risk stratification tool compared with conventional cytogenetic analysis.
Researchers sought to determine whether hypomagnesemia increases the risk of failure for autologous hematopoietic stem cell transplantation in patients with DLBCL.